KEAP1 and obesity disorder: Numerous studies demonstrated the dysregulation of Nrf2/Keap1/ARE pathways in many chronic diseases, including diabetes mellitus, obesity, and atherosclerosis (Cuadrado et al., 2019; da Costa et al., 2019).